Modern Radiation For Lymphoma
UPDATED ROLE AND NEW RULES

May 8-9, 2015

COURSE DIRECTOR
Joachim Yahalom MD
CHAIRMAN
International Lymphoma Radiation Oncology Group
MEMBER AND PROFESSOR
Memorial Sloan Kettering Cancer Center

CONFERENCE LOCATION
Memorial Sloan Kettering Cancer Center
ZUCKERMAN RESEARCH CENTER
417 East 68th Street, New York
(Between First and York Avenues)

NEW YORK CITY

Register today at:
www.mskcc.org/lymphomaradiation
COURSE OVERVIEW

Presentations of advances in clinical options and translational research for various lymphomas and clinical scenarios with a focus on the updated role of radiotherapy, modern RT technologies, and new guidelines for RT dose and fields.

Six travel grants will be awarded in the amounts of $500 for participants from North America and $1000 for participants from other continents.

COURSE DIRECTOR

Joachim Yahalom MD
Chairman, International Lymphoma Radiation Oncology Group
Member and Professor, MSK

HONORARY SPEAKERS

Saul Rosenberg MD
Stanford, CA, USA

Samuel Hellman MD
Chicago, IL, USA

Invited Speakers

Riccardo Dalla-Favera MD
New York, NY, USA

Andreas Engert MD
Cologne, Germany

Nancy Lee Harris MD
Boston, MA, USA

Gerhard Held MD
Saarland, Germany

Register today at:

www.mskcc.org/lymphomaradiation
SCIENTIFIC AGENDA:
MODERN RADIATION FOR LYMPHOMA
UPDATED ROLE AND NEW RULES

COURSE DIRECTOR
Joachim Yahalom MD
Chairman, International Lymphoma Radiation Oncology Group
Member and Professor, MSK

MSK SPEAKERS
Lisa DeAngelis, MD
Ahmet Dogan, MD, PhD
Steve Horwitz, MD
Craig Moskowitz, MD
Carol Portlock, MD
Anas Younes, MD
Andrew Zelenetz, MD, PhD

ILROG FACULTY SPEAKERS
Berthe Aleman, MD, PhD
Amsterdam, The Netherlands
Louis S. Constine, MD
Rochester, NY, USA
Bouthaina Dabaja, MD
Houston, TX, USA
Hans T. Eich, MD, PhD
Münster, Germany
David Hodgson, MD
Toronto, Ontario, Canada
Bradford Hoppe, MD
Jacksonville, FL, USA
Richard Hoppe, MD
Stanford, CA, USA
Theodore Girinsky, MD
Paris, France
Tim Illidge, MD, PhD
Manchester, England, UK
Youlia Kirova, MD
Paris, France
Yexiong Li, MD
Beijing, China
Peter Mauch, MD
Boston, MA, USA
George Mikhaeel, MD
London, England, UK
Andrea Ng, MD
Boston, MA, USA
Rahul Parikh, MD
New York, NY, USA
Umberto Ricardi, MD
Torino, Italy
Lena Specht, MD, PhD
Copenhagen, Denmark
Stephanie Terezakis, MD
Baltimore, MD, USA
Richard Tsang, MD
Toronto, Ontario, Canada
Andrew Wirth, MD
East Melbourne, Victoria, Australia

Register today at:
www.mskcc.org/lymphomaradiation
Friday, May 8: Morning

7:00-8:00am  REGISTRATION AND BREAKFAST

8:00-8:10am  INTRODUCTION
Joachim Yahalom, MD

8:10-8:20am  WELCOME
Jose Baselga, MD, Physician in Chief, MSK

8:20-9:00am  MEDICINE AND RADIATION ONCOLOGY GRAND ROUNDS
ILROG KEYNOTE LECTURE
“Milestones in the Treatment of Hodgkin Lymphoma: What’s Next?”
Andreas Engert, MD

9:00-9:15am  End of Grand Rounds (short break)

9:15-9:30am  INTRODUCTION OF SAUL ROSENBERG, MD
Richard Hoppe, MD

9:30-10:00am  Hodgkin’s Disease: A 50-Year Perspective
Saul Rosenberg, MD

10:00-10:15am  COFFEE BREAK

PATHOLOGY & IMMUNOLOGY SESSION
MODERATOR: Ahmet Dogan, MD, PhD

10:15-10:35am  WHO Lymphoma Classification Update
Nancy Lee Harris, MD

10:35-11:05am  “Hot” Issues in Lymphoma Pathology:
Impact of Genomic Studies on Diagnosis of Lymphoma
Ahmet Dogan, MD, PhD

11:05-11:35am  Molecular Pathogenesis of B Cell Lymphoma
Ricardo Dalla-Favera, MD

11:35am-12:00pm Immunological Modulation in the Treatment of Lymphoma:
Present and Future
Tim Illidge, MD, PhD
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-1:00pm</td>
<td><strong>LUNCH AND DIGITAL POSTER PRESENTATION</strong></td>
</tr>
<tr>
<td>1:00-1:10pm</td>
<td><strong>Introduction of Samuel Hellman, MD</strong></td>
</tr>
<tr>
<td>1:10-1:40pm</td>
<td><strong>What Thomas Hodgkin Can Teach Us</strong></td>
</tr>
<tr>
<td>1:40-2:00pm</td>
<td><strong>Staging and Response Assessment in Lymphoma</strong></td>
</tr>
<tr>
<td>2:00-2:20pm</td>
<td><strong>EORTC H10 and Future European Studies</strong></td>
</tr>
<tr>
<td>2:20-2:40pm</td>
<td><strong>HD6 and RAPID Study: Should It Change Practice?</strong></td>
</tr>
<tr>
<td>2:40-3:00pm</td>
<td><strong>Survival Analysis in Hodgkin Lymphoma: Large Data Bases</strong></td>
</tr>
<tr>
<td>3:00-3:15pm</td>
<td><strong>COFFEE BREAK</strong></td>
</tr>
<tr>
<td>3:15-4:15pm</td>
<td><strong>LOW RT DOSE STRATEGIES</strong></td>
</tr>
<tr>
<td>3:15-3:40pm</td>
<td><strong>Primary CNS Lymphoma</strong></td>
</tr>
<tr>
<td>3:40-4:00pm</td>
<td><strong>Indolent Lymphomas</strong></td>
</tr>
<tr>
<td>4:00-4:15pm</td>
<td><strong>COFFEE BREAK</strong></td>
</tr>
<tr>
<td>4:15-5:15pm</td>
<td><strong>CASE DISCUSSION:</strong> <strong>HODGKIN LYMPHOMA</strong></td>
</tr>
<tr>
<td></td>
<td><strong>MODERATOR:</strong> <strong>David Hodgson, MD</strong></td>
</tr>
<tr>
<td></td>
<td><strong>PANELISTS:</strong> <strong>Stephanie Terezakis, MD; Hans T. Eich, MD, PhD;</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Carol Portlock, MD; Peter Mauch, MD; Youlia Kirova, MD</strong></td>
</tr>
</tbody>
</table>
Saturday, May 9: Morning

7:00-8:00am  BREAKFAST

AGGRESSIVE LYMPHOMAS
MODERATOR: Bouthaina Dabaja, MD

8:00-8:20am  Biomarker Driven Treatment Selection in DLBCL
Andrew Zelenetz, MD, PhD

8:20-8:40am  The Role of Radiotherapy in the Treatment of DLBCL: A Perspective of The German High-Grade Non-Hodgkin Lymphoma Study Group
Gerhard Held, MD

8:40-9:00am  More Evidence of Benefit (and less toxicity) for Radiation Therapy in Large-Cell Lymphoma
Bouthaina Dabaja, MD

9:00-9:20am  High Dose Salvage for Non Hodgkin Lymphoma and Hodgkin Lymphoma
Craig Moskowitz, MD

9:20-9:45am  New Treatment Options in Lymphoma
Anas Younes, MD

9:45-10:00am  COFFEE BREAK

SKIN AND T-CELL LYMPHOMAS
MODERATOR: Richard Hoppe, MD

10:00-10:20am  Systemic Therapy for T-Cell Lymphoma
Steve Horwitz, MD

10:20-10:40am  Prognosis and Treatment of Extranodal NK/T-Cell Lymphoma, Nasal-Type
Yexiong Li, MD

10:40-11:00am  Radiotherapy of Mycosis Fungoides
Richard Hoppe, MD

11:00am-12:30pm  CASE DISCUSSION: NON-HODGKIN LYMPHOMA
MODERATOR: Bouthaina Dabaja, MD

11:00am-12:30pm  CASE DISCUSSION
PARTICIPANTS: Anas Younes, MD; Gerhard Held, MD; Richard Tsang, MD; Yexiong Li, MD

Register today at:
www.mskcc.org/lymphomaradiation
Saturday, May 9: Afternoon

12:30-2:00pm  LUNCH AND DIGITAL POSTER PRESENTATION
12:30-2:00pm  LUNCH AND MEETING OF THE STEERING COMMITTEE AND COUNCIL
2:00-3:00pm   NEW FIELDS CONCEPT AND NEW TECHNOLOGY
               MODERATOR: Umberto Ricardi, MD
2:00-2:20pm   Concepts of ISRT and DIBH
               Theodore Girinsky, MD
2:20-2:40pm   IMRT / IGRT Techniques: How Do We Decide About It?
               Umberto Ricardi, MD
2:40-3:00pm   Proton Therapy for Lymphoma: Pros and Cons
               Bradford Hoppe, MD
3:00-3:20pm   COFFEE BREAK
3:20-3:40pm   SECOND MALIGNANCIES
               Berthe Aleman, MD, PhD
3:40-4:00pm   The Heart after Lymphoma Therapy: The Beat Goes On (usually)!
               Louis S. Constine, MD
4:00-4:20pm   Surveillance and Prevention of Long-Term Morbidity
               Andrea Ng, MD
4:20-4:30pm   CONCLUSION
               Joachim Yahalom, MD
On the evening of Friday, May 8, join us to “Celebrate New York” at the Museum of the City of New York!

Included for you and a guest is a cocktail reception, dinner, and private tour of the galleries.

www.MCNY.org

RSVP by Thursday, April 30

www.surveymonkey.com/s/2015ILROGDinner
Saturday, May 9, 2015

ILROG LEADERSHIP DINNER

Metropolitan Museum of Art
1000 5th Avenue, New York

6:30pm Cocktail Reception
7:15pm Dinner
REGISTRATION

EARLY BIRD*  GENERAL
$250  $350  MDs, PhDs and DOs

$50  $50  Fellows, Residents and RNs

* Deadline is March 1, 2015.

Registration fee includes an electronic syllabus and other related hand-out materials, continental breakfast, lunch, and refreshment breaks. Special meals are available upon request, including vegetarian, kosher, or gluten-free. Please let us know if we can assist you with special dietary needs.

For more information or to register to attend please go to:

www.mskcc.org/lymphomaradiation

Or contact the:

OFFICE OF CONTINUING MEDICAL EDUCATION
Memorial Sloan Kettering Cancer Center
633 Third Avenue, 12th floor, New York, New York 10017
(646) 227-2025  •  brodheap@mskcc.org

TARGET AUDIENCE
Radiation oncologists and other health care professionals involved in treating patients with lymphoma.

COURSE DESIGN
Presentations of advances in clinical options and translational research for various lymphomas and clinical scenarios with a focus on the updated role of radiotherapy, modern RT technologies, and new guidelines for RT dose and fields.

EVALUATION
A course evaluation survey sent out electronically will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

ACCREDITATION STATEMENT
MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
MSK designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The AMA has determined that physicians not licensed in the United States but who participate in this CME activity are eligible for 13.5 AMA PRA Category 1 Credit(s)™.

FACULTY DISCLOSURE
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

OUTCOMES MEASUREMENT SURVEY
Six months after the end of the course an Outcomes Measurement Survey will be sent to all participants to help us determine what positive impacts have been made on participant practice as a result of the course.

HOTEL RESERVATIONS
For hotel availability and special rates close to MSK, go to: www.mskcc.org/accommodations. Please feel free to contact the CME Office for further assistance as needed at: johnsonf@mskcc.org
<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV and The Cancer Connection</td>
<td>April 8</td>
</tr>
<tr>
<td>Multidisciplinary Spine Oncology Symposium</td>
<td>Apr 17</td>
</tr>
<tr>
<td>LGBT Allies Training</td>
<td>April (TBD)</td>
</tr>
<tr>
<td>SCLC Conference</td>
<td>April 22-24</td>
</tr>
<tr>
<td>Pelvic MRI Course</td>
<td>April 27-29</td>
</tr>
<tr>
<td>Overuse: A Quality Problem In and Out of The Hospital</td>
<td>April 29</td>
</tr>
<tr>
<td>Care of the Older Adult Across The Cancer Continuum Symposium</td>
<td>May 1</td>
</tr>
<tr>
<td>LGBT Health Workforce</td>
<td>May 1-3</td>
</tr>
<tr>
<td>Pathology of Neoplastic Disease</td>
<td>May 4-8</td>
</tr>
<tr>
<td>Modern Radiation for Lymphoma</td>
<td>May 8, 9</td>
</tr>
<tr>
<td>Radioactive Seed Localization</td>
<td>May 11</td>
</tr>
<tr>
<td>Oncologic Imaging</td>
<td>May 14-16</td>
</tr>
<tr>
<td>Thrombosis and Hemostasis</td>
<td>May 17</td>
</tr>
<tr>
<td>SPARC</td>
<td>May 19</td>
</tr>
<tr>
<td>Ovarian Cancer</td>
<td>June 5-6</td>
</tr>
<tr>
<td>Trudy N. Small Symposium</td>
<td>June 19</td>
</tr>
<tr>
<td>Thoracic Pathology NYC</td>
<td>September 11-13</td>
</tr>
<tr>
<td>Robotics (w/ MDACC)</td>
<td>September 17-18</td>
</tr>
<tr>
<td>Endobronchial Ultrasound Interventional Bronchoscopy</td>
<td>September 24-25</td>
</tr>
<tr>
<td>Thoracic Surgical Oncology</td>
<td>October 2-3</td>
</tr>
<tr>
<td>Oncologic FDG PET/CT</td>
<td>October 9-10</td>
</tr>
<tr>
<td>Genetics and Genomics of Gynecologic Cancers</td>
<td>October 15-16</td>
</tr>
<tr>
<td>Defining the Actionable Genome</td>
<td>October 16-17</td>
</tr>
<tr>
<td>Spotlight On ALL</td>
<td>October 18</td>
</tr>
<tr>
<td>Dermatology Through The Lens of Medical Informatics</td>
<td>October 22</td>
</tr>
<tr>
<td>Dermatologic Care</td>
<td>October 23</td>
</tr>
<tr>
<td>Dermoscopy Intermediate</td>
<td>October 23-24</td>
</tr>
<tr>
<td>Musculoskeletal Tumor Pathology</td>
<td>October 23-25</td>
</tr>
<tr>
<td>Urologic Cancers</td>
<td>October 29-31</td>
</tr>
<tr>
<td>Complex Skin Cancers</td>
<td>November 20-22</td>
</tr>
<tr>
<td>International Ovarian Cancer</td>
<td>December 4-5</td>
</tr>
</tbody>
</table>

**ACCREDITATION STATEMENT**

MSK is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.